FDA clears breast biopsy device

June 12, 2002

Advanced Imaging Technologies has received marketing clearance from the FDA for a breast biopsy on its Avera Breast Imaging System. Unlike conventional ultrasound scanners, Avera uses diffractive, or "through-wave," ultrasound. The biopsy capability will

Advanced Imaging Technologies has received marketing clearance from the FDA for a breast biopsy on its Avera Breast Imaging System. Unlike conventional ultrasound scanners, Avera uses diffractive, or "through-wave," ultrasound. The biopsy capability will allow physicians to perform immediate biopsies on suspicious breast masses during an Avera imaging session, according to the company.